Moderna

mRNA therapeutics

MRNA · Nasdaq · United States

Share price · MRNA

$196.79+133.83 (+212.56%) 3M

close as of 2026-11-18 · 24h delayed · vol 7.0M (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MRNA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 19 Aug 2026+177.0%
  2. 10 Jul 2026-10.8%
  3. 26 Jun 2026+12.6%
  4. 22 Jun 2026-7.2%
  5. 17 Jun 2026+11.6%
  6. 16 Jun 2026+6.3%
  7. 5 Jun 2026-8.0%
  8. 3 Jun 2026+7.5%
  9. 8 May 2026+12.0%
  10. 4 Mar 2026+16.0%

    Nothing announced by MRNA that day or the session before.

Share of unusual movement by asset

For each asset, the share of MRNA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Intismeran Autogene
events and moves
3shown from 8 days
mRESVIA
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—78%
Other company news (earnings, financing, releases naming no asset)—6%
Sessions with no dated event—16%

Assets

(4 total)
4Total Assets
2Approved
1Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
elasomeran(Spikevax)
Approved
SARS-CoV-2 spike proteinVaccine
COVID-19
Approved
RSV pre-F proteinVaccine
Respiratory Syncytial Virus Infection
Phase 3
Patient-specific tumor neoantigens (personalized, up to 34 per patient)Vaccine
Non-Small Cell Lung CancerMelanoma
Phase 1/2
BCMA, GPRC5D, FcRH5RNA / oligonucleotide
Multiple Myeloma

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Intismeran AutogenePhase 1/2Bladder Cancer
Est. primary completion 2027-04-23 · NCT06305767 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Intismeran AutogenePhase 2Renal Cell Carcinoma
Est. primary completion 2028-01-08 · NCT06307431 · CT.gov ↗
What to watch
July 2028 (1)
Intismeran AutogenePhase 2Malignant Melanoma
Est. primary completion 2028-07-22 · NCT06961006 · CT.gov ↗
What to watch
2029 (2)
July 2029 (1)
Intismeran AutogenePhase 2Squamous Non-small Cell Lung Cancer
Est. primary completion 2029-07-02 · NCT07221474 · CT.gov ↗
What to watch
October 2029 (1)
Intismeran AutogenePhase 3Melanoma
Est. primary completion 2029-10-26 · NCT05933577 · CT.gov ↗
What to watch
2030 (2)
June 2030 (2)
mRNA-2808Phase 1/2Relapsed or Refractory Multiple Myeloma
Est. primary completion 2030-06-17 · NCT07116616 · CT.gov ↗
What to watch
Intismeran AutogenePhase 3Non-small Cell Lung Cancer
Est. primary completion 2030-06-25 · NCT06077760 · CT.gov ↗
What to watch
2031 (1)
September 2031 (1)
Intismeran AutogenePhase 2Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Est. primary completion 2031-09-03 · NCT06833073 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Intismeran AutogenePhase 2Melanoma
Est. primary completion 2032-11-21 · NCT03897881 · CT.gov ↗
What to watch
2033 (1)
May 2033 (1)
Intismeran AutogenePhase 3Carcinoma, Non-Small-Cell Lung
Est. primary completion 2033-05-16 · NCT06623422 · CT.gov ↗
What to watch
2034 (1)
August 2034 (1)
Intismeran AutogenePhase 3Non-small Cell Lung Cancer
Est. primary completion 2034-08-22 · NCT07513376 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 August 2026Topline resultIntismeran AutogeneINTerpath-001 Phase 3 of intismeran autogene plus pembrolizumab meets RFS primary endpoint in resected melanoma
Merck & Co. and Moderna · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.3B$583M$1.2B+ $4.0B short-term inv.—-$1.6B operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$145M$651M$1.7B+ $3.4B short-term inv.$782M-$526M operating cash flowreport ↗
2026-Q1$389M$649M$1.9B+ $3.3B short-term inv.$1.3B-$630M operating cash flowreport ↗
2025-Q3$1.0B$801M$1.1B+ $3.4B short-term inv.$200M-$847M operating cash flowreport ↗
2025-Q2$142M$700M$1.3B+ $3.9B short-term inv.$825M-$919M operating cash flowreport ↗
2025-Q1$108M$856M$1.6B+ $4.4B short-term inv.$971M-$1.0B operating cash flowreport ↗
2024-Q3$1.9B$1.1B$1.6B+ $5.2B short-term inv.—-$1.6B operating cash flowreport ↗
2024-Q2$241M$1.2B$2.5B+ $6.0B short-term inv.$1.3B-$1.3B operating cash flowreport ↗
2024-Q1$167M$1.1B$2.1B+ $6.5B short-term inv.$1.2B-$989M operating cash flowreport ↗
2023-Q3$1.8B$1.2B$3.0B+ $4.6B short-term inv.$3.6B-$1.6B operating cash flowreport ↗
2023-Q2$344M$1.1B$3.8B+ $4.7B short-term inv.$1.4B-$915M operating cash flowreport ↗
2023-Q1$1.9B$1.1B$3.5B+ $5.5B short-term inv.—-$1.2B operating cash flowreport ↗
2022-Q3$3.4B$820M$3.0B+ $5.3B short-term inv.—$252M operating cash flowreport ↗
2022-Q2—$710M$2.9B+ $5.0B short-term inv.—$304M operating cash flowreport ↗
2022-Q1—$554M$5.1B+ $5.1B short-term inv.—$2.8B operating cash flowreport ↗
2021-Q3—$521M$5.6B+ $3.4B short-term inv.—$3.3B operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.9B$3.1B$2.6B+ $3.2B short-term inv.$706M-$1.9B operating cash flowreport ↗

Moderna reported fiscal-year 2025 revenue of $1,944M, down 39.9% YoY from $3,236M, with R&D spend of $3,132M, down 31.1% YoY. The company reported a net loss of $2,822M for the year, cash and equivalents of $2,597M, and a full-year GAAP diluted EPS of $(7.26); fourth-quarter revenue was $678M with a net loss of $(826)M and GAAP EPS of $(2.11).

For 2026, Moderna reiterated plans for up to 10% revenue growth and GAAP operating expense reductions, with R&D projected at approximately $3.0B, cost of sales about $0.9B, and year-end cash and investments of $5.5B to $6.0B. Pipeline updates included regulatory review for its seasonal flu vaccine in the EU, Canada, and Australia, a U.S. FDA Refusal-to-File letter with a requested Type A meeting, full enrollment of the norovirus Phase 3 trial with a 2026 readout expected, and full enrollment of the Phase 2 intismeran autogene trial in muscle invasive bladder cancer.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$3.2B$4.5B$1.9B+ $5.1B short-term inv.$890M-$3.0B operating cash flowreport ↗
2023-FY$6.8B$4.8B$2.9B+ $5.7B short-term inv.$1.2B-$3.1B operating cash flowreport ↗
2022-FY$19.3B$3.3B$3.2B+ $6.7B short-term inv.—$5.0B operating cash flowreport ↗
2021-FY$18.5B$2.0B$6.9B+ $3.9B short-term inv.—$13.6B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 26 sales ($98.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17Hoge Stephen · PresidentOption exercise76,452$12.21$933KForm 4
2026-11-17Hoge Stephen · PresidentOpen-market sale33,976$211.45$7.2MForm 4
2026-11-17Hoge Stephen · PresidentOpen-market sale5,082$212.57$1.1MForm 4
2026-11-17Hoge Stephen · PresidentOpen-market sale157$214.19$34KForm 4
2026-11-17Hoge Stephen · PresidentOption exercise (derivative)76,452——Form 4
2026-11-16Hoge Stephen · PresidentOption exercise76,453$12.21$933KForm 4
2026-11-16Hoge Stephen · PresidentOpen-market sale39,160$219.66$8.6MForm 4
2026-11-16Hoge Stephen · PresidentGift400,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 716 reporting institutions held 308.2M shares ($15.5B, 76.2% of shares outstanding).

#InstitutionSharesValue
1FMR LLC45,672,024$2.3B
2BlackRock, Inc.29,635,876$1.5B
3VANGUARD CAPITAL MANAGEMENT LLC22,872,458$1.2B
4BAILLIE GIFFORD & CO19,985,876$1.0B
5Capital World Investors18,697,694$949.8M
6VANGUARD PORTFOLIO MANAGEMENT LLC15,616,367$793.3M
7STATE STREET CORP14,861,409$755.0M
8GEODE CAPITAL MANAGEMENT, LLC9,435,132$478.5M
9TWO SIGMA INVESTMENTS, LP9,086,404$461.6M
10MORGAN STANLEY8,471,263$430.3M
11Theleme Partners LLP8,048,245$408.9M
12GOLDMAN SACHS GROUP INC6,603,697$335.5M
13Invesco Ltd.4,784,758$243.1M
14CHARLES SCHWAB INVESTMENT MANAGEMENT INC4,734,356$240.5M
15Flagship Pioneering, LLC4,632,149$235.3M